ABCL-406 Real-World Sequential Use of CD19-Directed Therapies for Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Tafasitamab Preceding Chimeric Antigen Receptor T-Cell (CAR-T) Therapy

Category Primary study
JournalClinical Lymphoma, Myeloma and Leukemia
Year 2024
This article has no abstract
Epistemonikos ID: 205be2e6552d12e55e964857d68eb89fd22a2f43
First added on: Feb 18, 2025